Daktari Diagnostics Inc. pulled in $1.8 million, according to a Securities & Exchange Commission filing.
The Cambridge, Mass.-based developer of a point-of-care HIV test raised the equity-based financing from 32 unnamed investors, according to SEC document.
The filing names as directors Norwich Ventures managing director Aaron Sandoski, Mi3 Venture Partners partner Roger Kitterman, MIT Sloan School of Management professor Edward Roberts, SynapDx Corp. founder Stanley Lapidus, and Daktari CEO William Rodriguez. Each one of the men is named on previous securities filings.
The company’s hand-held device is designed to count CD4 cells in the bloodstream and determine the body’s ability to fight infection. CD4 counts also are one of the primary methods to assess the progress of HIV/AIDS. Current testing involves drawing blood from the patient and sending the sample to a lab — a time-consuming and costly process in many parts of Africa and other developing countries where AIDS is prevalent.